---
schema_version: "secwatch.filing_event.v1"
accession: "0001804585-23-000007"
form_type: "8-K"
ticker: null
cik: "0001804585"
company_name: "NUGENEREX IMMUNO-ONCOLOGY, INC."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:41:15.997593+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Beijing Youfeng acquires 64% of NuGenerex for $3.35M in bankruptcy; new board and CEO appointed

## Summary
- Beijing Youfeng Biological Technology acquired 64,153,151 common shares (63.96%) and 100% of Series A Super Voting Preferred on March 3, 2023 for $3.35 million.
- Control assumed from Chapter 7 Trustee Marc P. Barmat of Generex Biotechnology's bankruptcy estate.
- On March 15, 2023, majority shareholder elected new directors: XiaoYan Wang, Feng Wang, and Kevin McGovern via written consent.
- New board on March 21, 2023 removed all officers except Dr. Eric von Hofe; appointed Feng Wang as CEO, Secretary, Treasurer; von Hofe as President and CSO.

## SEC filing metadata
- accession: 0001804585-23-000007
- form_type: 8-K
- cik: 0001804585
- company_name: NUGENEREX IMMUNO-ONCOLOGY, INC.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.01, 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/0001804585-23-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/plain8k.txt

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804585-23-000007
- JSON: https://secwatch.observer/filing/0001804585-23-000007.json
- Plain text: https://secwatch.observer/filing/0001804585-23-000007.txt

## Key facts
- M&A Transactions
  NUGENEREX IMMUNO-ONCOLOGY, INC. underwent a change of control involving Beijing Youfeng Biological Technology Co., Ltd. for $3.35 million (closed 2023-03-03).
  - Action: change of control
  - Counterparty: Beijing Youfeng Biological Technology Co., Ltd.
  - Consideration: $3.35 million
  - Closing: 2023-03-03
  source text: District of Florida, Fort Lauderdale Division on February 7, 2023, Beijing Youfeng Biological Technology Co., Ltd. and the Chapter 7 Trustee allocate the purchase price of $3.35 million for the equity and assigned claims of Generex Biotechnology Corporation such as they agree. (5) the source(s) of funds used by the person(s); and (6) the identity of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/0001804585-23-000007-index.htm
- Shareholder Votes
  NUGENEREX IMMUNO-ONCOLOGY, INC. shareholders approved Election of directors by written consent of majority shareholder at the 2023-03-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-03-15
  source text: XiaoYan (Maggie) Wang, Feng (Anthony) Wang and Kevin McGovern were elected as the new directors of NGIO without a meeting, through the written consent of the majority shareholder dated March 15, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/0001804585-23-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.